Assenagon Asset Management S.A. Reduces Holdings in DaVita Inc. $DVA

Assenagon Asset Management S.A. decreased its position in shares of DaVita Inc. (NYSE:DVA) by 37.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 42,628 shares of the company’s stock after selling 25,780 shares during the period. Assenagon Asset Management S.A.’s holdings in DaVita were worth $4,843,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently made changes to their positions in DVA. Elevation Wealth Partners LLC boosted its stake in shares of DaVita by 147.3% during the 4th quarter. Elevation Wealth Partners LLC now owns 277 shares of the company’s stock worth $31,000 after purchasing an additional 165 shares during the period. Canada Pension Plan Investment Board bought a new position in DaVita during the 2nd quarter valued at about $43,000. iSAM Funds UK Ltd purchased a new stake in DaVita in the 3rd quarter worth about $46,000. Stance Capital LLC bought a new stake in DaVita in the third quarter worth about $47,000. Finally, Employees Retirement System of Texas bought a new stake in DaVita in the second quarter worth about $49,000. Institutional investors own 90.12% of the company’s stock.

DaVita Trading Down 1.5%

DVA opened at $154.43 on Friday. The company has a market capitalization of $10.32 billion, a price-to-earnings ratio of 15.58, a PEG ratio of 0.54 and a beta of 0.94. DaVita Inc. has a 12-month low of $101.00 and a 12-month high of $159.42. The business’s fifty day simple moving average is $140.32 and its 200-day simple moving average is $128.15.

DaVita (NYSE:DVA) last released its quarterly earnings data on Monday, February 2nd. The company reported $3.40 earnings per share for the quarter, beating the consensus estimate of $3.24 by $0.16. DaVita had a negative return on equity of 413.18% and a net margin of 5.47%.The firm had revenue of $3.62 billion during the quarter, compared to the consensus estimate of $3.51 billion. During the same period in the previous year, the company posted $2.24 earnings per share. The firm’s quarterly revenue was up 9.9% on a year-over-year basis. DaVita has set its FY 2026 guidance at 13.600-15.00 EPS. On average, equities research analysts predict that DaVita Inc. will post 10.76 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on DVA shares. Zacks Research raised DaVita from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, February 4th. Weiss Ratings restated a “hold (c)” rating on shares of DaVita in a report on Monday, December 29th. Truist Financial set a $158.00 price objective on DaVita in a research report on Thursday, February 5th. UBS Group increased their target price on DaVita from $186.00 to $190.00 and gave the stock a “buy” rating in a research note on Wednesday, February 4th. Finally, Barclays lifted their target price on DaVita from $143.00 to $158.00 and gave the stock an “equal weight” rating in a research report on Tuesday, February 3rd. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $155.80.

DaVita Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.